Skip to main
GKOS
GKOS logo

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Glaukos Corp has demonstrated significant growth in its glaucoma revenue, achieving $110 million in the third quarter of 2025, surpassing consensus estimates and reflecting a 45% increase year-over-year, with notable domestic sales up 57%. The company's operating margin improved to (7.0%), showing a substantial year-over-year increase of 1,210 basis points and exceeding market expectations. Additionally, Glaukos's Corneal Health segment has experienced a robust compound annual growth rate (CAGR) of approximately 15.2% globally since 2020, with positive adoption trends for its Epioxa therapy indicating increased future utilization among potential adopters.

Bears say

Glaukos Corp faces significant headwinds that contribute to a negative outlook on its stock, primarily due to projected slower growth in the micro-invasive glaucoma surgery (MIGS) market and challenges in the adoption of its iDose TR and iStent infinite products. Sales data indicates a concerning decline in legacy surgical glaucoma products, with a reported 4.7% decrease, along with expectations of a material decline in corneal health revenues as it transitions to the Epioxa product. Additionally, potential alterations in the reimbursement landscape and slower-than-anticipated product launches further intensify the risks associated with Glaukos's future financial performance.

Glaukos (GKOS) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 13 analysts, Glaukos (GKOS) has a Buy consensus rating as of Nov 7, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $122.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $122.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.